Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

GEN3018

Phase 1Biologic

GEN3018 is one of 9 biologic programs targeting R/R AML. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

8

Competitors

Pipeline

Status by Indication[3][1]

Indication

R/R AMLRecruiting

R/R AMLPhase 1

Recruiting

Competition

Competitive Landscape

9 competitors in R/R AML

#DrugCompanyPhaseTrials

Fludara

Cytoxan

BBaxter Healthcare Corporation

Ibrance

Tazverik

Komzifti

KKura Oncology, Inc.

Mezigdomide

Bristol-Myers Squibb

Liposome-Encapsulated Daunorubicin-Cytarabine

MM.D. Anderson Cancer Center

GEN3018

Hydroxycarbamid

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1Recruiting

R/R AML

NCT07384715

Clinical

Trials by Indication[1]

R/R AML1 trial

An Open-Label, Multicenter, First-in-Human Trial of GEN3018 in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Recruiting· Genmab logo

Genmab·Phase 1·NCT07384715·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GEN3018. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GEN3018 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GEN3018. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genmab company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: Genmab

Related News